Division of Medicinal Chemistry Centennial Celebration – Washington DC

The Division of Medicinal Chemistry will celebrate 100 years of excellence at the ACS meeting held in Washington, DC (August 16-20, 2009). In order to commemorate this milestone, a special Centennial Symposium will be held at the Washington, DC ACS meeting on Wednesday, August 19, 2009. This symposium will begin at 3:00 pm in Ballroom C of the Washington Convention Center. Five lectures are scheduled as part of this session, including:

- Patrick M. Woster: The Division of Medicinal Chemistry from 1909 to 2009: 100 Years of Excellence.
- Philip S. Portoghese: Relevance of heteromeric receptors as targets for opioid analgesics.
- Magid Abou-Gharbia: Strategies for the discovery of innovative small molecule therapeutics.
- Paul Anderson: Medicinal chemistry: Then and now.

The celebration will continue at the annual Hall of Fame Ceremony, which will begin immediately following the symposium in Ballroom A. The HOF event will include a book signing by John LaMattina, where copies of his book 'Drug Truths' will be given out to Division members. Finally, a special issue of the Journal of Medicinal Chemistry will be published in the fall of 2009, edited by Bruce Maryanoff, John Macor and Brian Blagg. It will feature a short history of the Division, as well as a number of high-quality scientific papers selected by the editors.

NEW Abstracts for the Washington, DC ACS Meeting
Now Available for Download

Follow the link below to download the MEDI abstracts for the Washington, DC ACS meeting


Scientific Program for the Washington D.C. ACS Meeting (August 16-20, 2009)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUN AM</td>
<td></td>
<td>General Oral Session I</td>
</tr>
<tr>
<td>SUN AM</td>
<td></td>
<td>Joint Chinese/US Session: Hot Topics</td>
</tr>
<tr>
<td>SUN PM</td>
<td></td>
<td>RNA/Targeted Control of Gene Expression</td>
</tr>
<tr>
<td>SUN EVE</td>
<td></td>
<td>Poster Session I and Social Hour</td>
</tr>
<tr>
<td>MON AM</td>
<td></td>
<td>MEDI Award Symposium</td>
</tr>
<tr>
<td>MON PM</td>
<td></td>
<td>Small Molecules &amp; Rheumatoid Arthritis</td>
</tr>
<tr>
<td>MON PM</td>
<td></td>
<td>Macrocyclization in Drug Design</td>
</tr>
<tr>
<td>TUES AM</td>
<td></td>
<td>PARP Inhibitors</td>
</tr>
<tr>
<td>TUES AM</td>
<td></td>
<td>Allosteric Approaches to Drug Discovery</td>
</tr>
<tr>
<td>TUES NOON</td>
<td></td>
<td>Lunch and Learn Case Study</td>
</tr>
<tr>
<td>TUES PM</td>
<td></td>
<td>General Oral Session II</td>
</tr>
<tr>
<td>TUES PM</td>
<td></td>
<td>Energetics of Drug-Receptor Binding</td>
</tr>
<tr>
<td>WED AM</td>
<td></td>
<td>Inflammation and Immunology Therapies</td>
</tr>
<tr>
<td>WED PM</td>
<td></td>
<td>Phosphatases and Kinases</td>
</tr>
<tr>
<td>WED PM</td>
<td></td>
<td>Fine-Tuning Anticancer Drugs</td>
</tr>
<tr>
<td>WED PM</td>
<td></td>
<td>MEDI Centennial Symposium</td>
</tr>
<tr>
<td>WED EVE</td>
<td></td>
<td>Hall of Fame Award Ceremony</td>
</tr>
<tr>
<td>WED EVE</td>
<td></td>
<td>Poster Session II</td>
</tr>
<tr>
<td>THURS AM</td>
<td></td>
<td>General Oral Session III</td>
</tr>
<tr>
<td>THURS AM</td>
<td></td>
<td>Treatments for Insomnia</td>
</tr>
<tr>
<td>THURS PM</td>
<td></td>
<td>General Oral Session IV</td>
</tr>
</tbody>
</table>

Preliminary Program: San Francisco ACS Meeting (March 21-25, 2010)

OASYS open August 24, closes October 19, 2009

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUN AM</td>
<td></td>
<td>General Oral Session I</td>
</tr>
<tr>
<td>SUN AM</td>
<td></td>
<td>Modulating β-Amyloid Production</td>
</tr>
<tr>
<td>SUN PM</td>
<td></td>
<td>First Time Disclosures</td>
</tr>
<tr>
<td>SUN EVE</td>
<td></td>
<td>Poster Session I and Social Hour</td>
</tr>
<tr>
<td>MON AM</td>
<td></td>
<td>NPC1L1/Cholesterol Absorp. Inhib.</td>
</tr>
<tr>
<td>MON AM</td>
<td></td>
<td>Rare and Orphan Diseases</td>
</tr>
<tr>
<td>MON PM</td>
<td></td>
<td>Mapping Target Binding Cavities</td>
</tr>
<tr>
<td>MON PM</td>
<td></td>
<td>Six Sigma</td>
</tr>
<tr>
<td>TUES AM</td>
<td></td>
<td>Targeting Thyroid Hormone Action</td>
</tr>
<tr>
<td>TUES NOON</td>
<td></td>
<td>Lunch and Learn Case Study</td>
</tr>
<tr>
<td>TUES PM</td>
<td></td>
<td>General Oral Session II</td>
</tr>
<tr>
<td>TUES PM</td>
<td></td>
<td>Mimicking Bariatric Surg. in Diabetes</td>
</tr>
<tr>
<td>WED AM</td>
<td></td>
<td>Beyond Amides: New Peptide Therapies</td>
</tr>
<tr>
<td>WED PM</td>
<td></td>
<td>Prodrugs to Improve Oral Bioavail.</td>
</tr>
<tr>
<td>WED PM</td>
<td></td>
<td>Nuclear Hormone Receptors (Tribute to Ron Magolda)</td>
</tr>
<tr>
<td>WED EVE</td>
<td></td>
<td>Poster Session II</td>
</tr>
<tr>
<td>THURS AM</td>
<td></td>
<td>General Oral Session III</td>
</tr>
<tr>
<td>THURS AM</td>
<td></td>
<td>Selective CCK Receptor Modulators</td>
</tr>
<tr>
<td>THURS PM</td>
<td></td>
<td>General Oral Session IV</td>
</tr>
</tbody>
</table>
**Division Travel Grants**

The Division of Medicinal Chemistry makes 14 grants of $600 - $1000 available annually to aid young chemists in presenting papers at the ACS National Meetings. Applicants must be ACS regular or student members, and not have previously received a travel award. Each University department can have only one awardee. Application deadlines are the same as the abstract deadline for each meeting. In order of priority, the following individuals will be considered for awards: Graduate Student, Postdoctoral Fellow, individual with less than five years post-Ph.D. experience. The scientific merit of the paper to be presented will also be considered. Send applications to:

Jeff Zablocki, Ph.D.
CV Therapeutics, Inc.
3172 Porter Drive
Palo Alto, CA 94304
(650) 384-8547
jeff.zablocki@cvt.com

Awardees will be notified in sufficient time so that they can pre-register for the meeting. **All travel grant recipients are required to acknowledge the Division in a slide or on their poster as a condition of accepting the award.** Awards are made at the Division business meeting, which is held at each national meeting immediately before the Sunday night poster session and mixer. Address info and a complete application appears on page 3.

---

**Invitation to Authors: Journal of Medicinal Chemistry Perspective Series**

The Perspective series of the *Journal of Medicinal Chemistry* is designed to provide an enlightened appraisal of a field of research in which experts review the state-of-the-art for a given area or therapeutic target. Authors have editorial freedom to express their views on the strategic directions of the field of research. The Perspective series provides a forum with high visibility within the pharmaceutical industry and academia. We would like to identify a wide range of potential topics and authors to ensure that a Perspective article is published in every issue of the Journal. We would like the series to be useful to a broad range of scientists interested in the design, discovery and development of novel medicines. We invite you to submit an idea for a Perspective, along with a brief outline of what you will cover in the manuscript. We also welcome your input regarding potential topics of interest and authors for Perspective manuscripts. Please direct correspondence or calls regarding the series to:

William J. Greenlee
Schering-Plough Research Institute
2015 Galloping Hill Road
Kenilworth, NJ 07033
Phone (908)-740-2220
FAX (908)-740-7164
william.greenlee@spcorp.com

---

**CALL FOR PAPERS**

**239th NATIONAL ACS MEETING**

San Francisco, CA, March 21-25, 2010

**Abstracts Due October 19, 2009**

You are invited to submit an abstract for a research presentation at the 239th National Meeting of the American Chemical Society, to be held March 21-25, 2010 in San Francisco, CA. All abstracts should be submitted online using the OASYS system, which will open on August 24, 2009 for the San Francisco meeting. The deadline for submission of abstracts is October 19, 2009. This date will also be the deadline for submission of travel grant applications, as outlined on page 3 of this Newsletter. Please watch the Division Homepage, located at:

http://www.acsmedchem.org/

for additional information. The MEDI scientific program and abstracts will be available for download 3-4 weeks prior to the meeting, and their availability will be announced by electronic mail. For more information on programming or abstract submission, contact the Program Chair, Jeff Zablocki, at

jeff.zablocki@cvt.com

---

**Division Archives Available On-line**

Division newsletters, scientific programs and abstract books dating to 2002 are archived online. These documents can be downloaded in pdf format through the Division WWW page:

http://www.acsmedchem.org
ACS Division of Medicinal Chemistry Student Travel Grants

APPLICANTS MUST SUBMIT AN ABSTRACT SEPARATELY VIA OASYS SYSTEM

The deadline for Travel Grant applications is the same as the abstract deadline for that meeting. All travel grant recipients are required to acknowledge the Division in a slide during oral presentations, or on their poster as a condition of accepting the award.

* Name of Applicant for Travel Grant ________________________________

* Degree: ______________ Year Obtained ________________________________

* Present Institution: _________________________________________________

* Department: _________________________________________________________

*E-mail Address: _____________________________________________________________________

* Work to be reported was (check one or more):
  a. Ph.D. Thesis _______
  b. M.S. Thesis _______
  c. Postdoctoral Fellowship _______

*Supported by (indicate source of support for this work):
  a. Grant ___________________
  b. Department ___________________
  c. Other ___________________

Send the completed application form and a copy of the OASYS abstract to:

Jeff Zablocki, Ph.D.
CV Therapeutics, Inc.
3172 Porter Drive
Palo Alto, CA 94304
(650) 384-8547
jeff.zablocki@cvt.com
Dr. Kenneth A. Jacobson received his B.A. in Liberal Arts from Reed College in Portland, Oregon and his M.S. and Ph.D. (1981) in Chemistry with Prof. Murray Goodman at the University of California, San Diego. After completing his postdoctoral work with Prof. A. Patchornik at the Dept. of Organic Chemistry, Weizmann Institute in Israel, he joined the National Institute of Diabetes & Digestive and Kidney Diseases at NIH in Bethesda, MD in 1983. He currently serves as Chief of both the Molecular Recognition Section, which he founded in 1993, and the Laboratory of Bioorganic Chemistry. He began the NIDDK Chemical Biology Core Laboratory as Director in 2003.

His creativity and his ability to combine the field of chemistry with those of pharmacology and molecular biology have had a major impact on biomedical research and therapeutic development. Over the course of two decades at NIH, Dr. Jacobson has made major contributions to the pharmacology of cell surface receptors, in particular purinergic receptors. He has studied recognition at the binding sites of G protein-coupled receptors (GPCRs) by structural modification, both from the perspective of the small molecular ligands and of their protein targets. His group began the computer modeling of adenosine receptors as a tool for interpreting site-directed mutagenesis data soon after their cloning. Early in his career he pioneered the concept of “functionalized congeners,” a now widely used approach in drug development, which has recently led to the design of multivalent conjugates of GPCR ligands using dendrimers as nanocarriers. He also introduced the concept of “neocceptors” as a strategy for re-engineering the binding site of a GPCR for activation by chemically tailored small molecules. His research has led to agents in clinical trials for cystic fibrosis, cancer, degenerative diseases, and autoimmune inflammatory diseases. Two nucleosides from the Jacobson laboratory that act as selective A3 adenosine receptor agonists are currently in clinical trials for rheumatoid arthritis, hepatocarcinoma, psoriasis, and dry eye disease. Dozens of ligands used as pharmacological probes in research on adenosine receptors and P2 (nucleotide) receptors were introduced by Dr. Jacobson and colleagues. Many of these substances bear the designation “MRS” after the name of his Section.

Dr. Jacobson has authored or co-authored over 500 scientific publications and is an inventor on 35 issued U.S. patents. He has served the ACS Division of Medicinal Chemistry as Chair in 2004 and has planned and chaired numerous symposia at ACS National Meetings. Dr. Jacobson is or has been on the editorial advisory boards of the Journal of Medicinal Chemistry, Bioconjugate Chemistry, Molecular Pharmacology, Current Topics in Medicinal Chemistry, Medicinal Research Reviews, and Future Medicinal Chemistry, and he is an Associate Editor of Purinergic Signalling. He has mentored 63 postdoctoral fellows, both chemists and biologists. He received the 2003 Hillebrand Prize, the 2008 Sato International Memorial Prize from the Pharmaceutical Soc. of Japan, and the 2009 Pharmacia-ASPET Award from the American Soc. for Pharmacology and Experimental Therapeutics. Dr. Jacobson was recently included in a listing of the ten most cited researchers in the field of pharmacology.

Dr. Malcolm MacCoss obtained his Ph.D. in organic chemistry from the University of Birmingham in the U.K. in 1971, working with Professors A.S. Jones and R.T. Walker, and then carried out a post-doctoral fellowship and a research associateship at the University of Alberta in Canada from 1972-1976, working with Professor M.J. Robins. During those times he worked in the field of nucleoside and nucleic acid chemistry. He then moved to the U.S.A. and took up an appointment at Argonne National Laboratory in Illinois where he continued to work on nucleic acid chemistry and the solution structure of nucleic acid components by NMR spectroscopy. While at Argonne he won the University of Chicago Medal for Distinguished Performance at Argonne National Laboratory (awarded to scientists under 40) and he also held a joint appointment as an Adjunct Associate Professor in the Medicinal Chemistry Department at the University of Illinois at the Medical Center. Dr. MacCoss began his career at Merck as a Research Fellow in 1982, and rose through the ranks to Vice President Basic Chemistry - Rahway in 1999. In 2003 he became the Vice President of Basic Chemistry and Drug Discovery Sciences, and the Deputy Site-Head of the Rahway Site. He is also the Head of the Merck World-Wide Chemistry Council.

When he was an active research scientist, Dr. MacCoss led a medicinal chemistry group that synthesized Emend® (aprepitant) which is a Merck anti-emetic product for the treatment of chemotherapy induced nausea and vomiting, for which he was awarded the Thomas Edison Award in 2004, along with the other inventors. He is also a co-inventor on the patents that describe Januvia® (sitagliptin phosphate) Merck’s new dipeptidyl peptidase 4 (DPP-4) inhibitor and Janumet® (sitagliptin plus metformin). In addition, Dr. MacCoss has authored or co-authored over 140 publications in refereed journals, is an inventor on 91 issued U.S. patents, has authored 7 book chapters and has been an invited speaker at 29 major symposia.
Dr. Richard B. Silverman, the John Evans Professor of Chemistry at Northwestern University, teaches organic chemistry, medicinal chemistry, and enzyme chemistry and carries out research in the area of medicinal chemistry, particularly related to potential treatments for neurodegenerative diseases. Silverman received his PhD in organic chemistry from Harvard University in 1974. After two years as a NIH postdoctoral fellow at Brandeis University, he joined the chemistry faculty at Northwestern University. Silverman has published over 250 research articles, holds 42 domestic and foreign patents, and has written four books. He is the inventor of Lyrica® (pregabalin), a blockbuster drug marketed worldwide by Pfizer for refractory epilepsy, neuropathic pain, fibromyalgia, and (in Europe) for generalized anxiety disorder. Awards include: DuPont Young Faculty Fellow (1976), Alfred P. Sloan Research Fellow (1981-1985), NIH Research Career Development Award (1982-1987), Fellow of the American Institute of Chemists (1985), Fellow of the American Association for the Advancement of Science (1990), Arthur C. Cope Senior Scholar Award of the American Chemical Society (2003), Alumni Fellow Award of Pennsylvania State University (2008), and the Perkin Medal from the Society of Chemical Industry (2009). He is the recipient of several teaching awards, including the E. LeRoy Hall Award for Teaching Excellence and the Excellence in Chemistry Education Award from the Northwestern University Chapter of Alpha Chi Sigma Chemistry Fraternity (1999), the Northwestern University Alumni Teaching Award (2000), and the Charles Deering McCormick Chair in Teaching Excellence (2001). He is or has been on the editorial advisory boards of eight professional journals. Silverman and his wife, Barbara, have three children, two in New York and one in Seattle.

Pre-Register for the Lunch and Learn Session at the Washington DC ACS Meeting

**From Needle to Pill:**
_Exjade, an Orally Active Iron Chelator_

**Speakers:**
- Hanspeter Nick - Biology
- Carsten Spanka - Medicinal Chemistry
- René Lattmann - Medicinal Chemistry
- Victor Dong - Clinical

_Novartis_  
_Walter E. Washington Convention Center_  
_Tuesday, August 18, 2009_  
_Noon to 2 PM_  
_$20 per person_  
_Purchase Ticket when Registering for Meeting_

To pre-register:

Add the event when you pre-register for the Washington DC ACS meeting:

https://www.xpressreg.net/register/acsf089/start.asp

Already pre-registered? Add this event to your account:

https://www.xpressreg.net/register/acsf089/xpresstoolkit/login.asp

Select the Add Social Events link to sign up. Registration code SE-17
Even More Tools for *In Silico* Prediction

ACD/Labs has been at the forefront of physicochemical prediction for nearly 15 years. Now, we’ve added a new dimension to our expert software for lead optimization and structure-based drug design with ADME and Toxicity screening and prediction. Get more of the tools you need from a source you already know for high quality *in silico* prediction.

**ADME Boxes**
Predict ADME properties including blood-brain barrier permeation, Absolv, P-gp, oral bioavailability absorption, and distribution

**Tox Boxes**
Predict, genotoxicity, hERG inhibition, acute toxicity, and organ-specific health effects

**DMSO Solubility**
Calculate the distribution of compounds in DMSO

**ACD/PhysChem Suite**
A complete array of tools for the prediction of molecular physical properties including pKₐ, logP, logD, and pH-dependent aqueous solubility

**ACD/Structure Design Suite**
Explore novel substituent modifications to enhance lead optimization and drug design in an intelligent and systematic way

Advanced Chemistry Development, Inc. (ACD/Labs) and Pharma Algorithms, Inc., have joined forces. The entire Pharma Algorithms product line—including modeling software for ADME, Toxicology, and DMSO Solubility—are now part of ACD/Labs’ product portfolio.

Meet us at the ACS Fall National Meeting *Booth #1123*

Visit [www.acdlabs.com/acsmedchem/](http://www.acdlabs.com/acsmedchem/)
Nine Students Selected to Receive ACSMEDI Predoctoral Fellowships

The Division of Medicinal Chemistry is pleased to announce that nine graduate students have been selected to receive 2009-2010 Predoctoral Fellowships. The awards, consisting of a $24,000 stipend, are granted to predoctoral students in their third or fourth year of graduate study. Winners must be engaged in medicinal chemistry research in a Medicinal Chemistry, Pharmaceutical Chemistry, Biochemistry, or Chemistry department listed in the current ACS Directory of Graduate Research. They must also be U.S. citizens or permanent resident visa holders, and must have at least one year of graduate school remaining as of September, 2009. Seven of these awards are supported through the generosity of pharmaceutical companies (as indicated below), while two are supported by the Division. The awardees for the 2009-2010 academic year are:

Amanda Fenner, Dept. of Medicinal Chemistry, Univ. of Iowa (Advisor: Robert J. Kerns; Sponsor: Bristol-Myers Squibb)
Caleb Woods, Dept. of Medicinal Chemistry, Univ. of Washington (Advisor: William A. Atkins; Sponsor: Pfizer)
Chris Cabello, Dept. of Pharmacology and Toxicology, Univ. of Arizona (Advisor: George Wondrak; Sponsor: Novartis)

Jacob Houghton, Dept. of Medicinal Chemistry, Univ. of Michigan (Advisor: Sylvie Garneau-Tsodikova; Sponsor: Eli Lilly)
Jamin Steffen, Dept. of Pharmacology and Toxicology, Univ. of Arizona (Advisor: Myron K. Jacobson; Sponsor: Amgen)
John McIntosh, Dept. of Medicinal Chemistry, Univ. of Utah (Advisor: Eric W. Schmidt; Sponsor: Sanofi-Aventis)

Kyle V. Butler, Dept. of Medicinal Chemistry and Pharmacognosy, Univ. of Illinois at Chicago (Advisor: John F. Fitzloff; Sponsor: The Division of Medicinal Chemistry)
Nicholas Smith, Dept. of Chemistry, Texas Christian Univ. (Advisor: Sergei Dzyuba; Sponsor: Wyeth)
Quinn Peterson, Dept. of Chemistry, Univ. of Illinois (Advisor: Paul J. Hergenrother; Sponsor: The Division of Medicinal Chemistry)

The Division of Medicinal Chemistry would like to thank the sponsors of the Predoctoral Fellowship awards for their generosity and support, and extend congratulations to the winners.
7th ISCMC
February 1-5, 2010
KaoHsiung, Taiwan

Opportunities and challenges for the treatment of Metabolic Syndrome
(symposium sponsored by ACS)
**Division News in RSS Format**

ACSMEDI news and announcements are now posted periodically on the Division RSS feed. RSS (Really Simple Syndication) continually delivers the latest news directly to your reader (also known as a News Aggregator). RSS feeds have an URL just like a web page, except that they end in .rss or .xml. They are marked on most web pages with a red logo that either says XML or RSS. Most web browsers now have seamless support for RSS, and the list for each of your subscriptions is updated automatically. When you visit a web page, click on the red icon to get the RSS address. **Members are encouraged to utilize this technology to receive Division news. This will help us minimize the number of emails sent out by the Division.** For more information on using the Division RSS feed, go to:

http://www.acsmedchem.org

and click on the red RSS link to access the feed. You may direct all questions to the Division webmaster.

---

**Be a Guest Editor for and Issue of Current Topics in Medicinal Chemistry**

Current Topics in Medicinal Chemistry (CTMC, [http://www.bentham.org/ctmc](http://www.bentham.org/ctmc)) is in its 8th year, and has an impact factor of 4.3, placing it among the more cited journals in Medicinal Chemistry. CTMC now has opportunities available to be a Guest Editor, and anyone interested in preparing and editing an issue should please suggest one or more possible topics to:

Allen Reitz, Ph.D.  
CTMC Editor  
Allen.Reitz@ihvr.org

CTMC issues consist of 6-12 manuscripts focused on a common theme in Medicinal Chemistry, Chemical Biology or a related discipline. The Guest Editor would be added to the Editorial Advisory Board of CTMC and be in control of all aspects of editorial review of their issue. This is a great opportunity to have a positive impact on a new or emerging area of research.

---

**Advertise in the ACSMEDI Newsletter**

The ACSMEDI Newsletter is distributed twice a year to 10,500 medicinal and organic chemist members, and is freely accessible to all through the ACSMEDI homepage. In response to a number of inquiries, we have established the following advertising policy:

- One-quarter page: $350.00
- One-half page: $500.00
- Full page: $900.00

To place an ad or obtain more information, contact the editor at pwoster@wayne.edu

---

**Sponsorship for Division of Medicinal Chemistry Symposia**

Division of Medicinal Chemistry symposia at National Meetings are presented in part through the financial support of sponsor companies. Sponsorship opportunities are available for all upcoming Division of Medicinal Chemistry Symposia. Symposium sponsors for national ACS meetings are acknowledged with a prominent sign outside the meeting room, and by session chairs during the symposium. In addition, a table is provided where company representatives can interact with meeting attendees, and provide promotional materials. For more information on symposium sponsorship, contact the Program Chair, Jeff Zablocki ([jeff.zablocki@cvt.com](mailto:jeff.zablocki@cvt.com)) or the Division Chair, Jim McCarthy ([james.ray.mccarthy@gmail.com](mailto:james.ray.mccarthy@gmail.com)).
1. Regular Executive Committee Members

Chair 2009
James R. McCarthy, Ph.D.
Department of Chemistry and Chemical Biology
Indiana University Purdue University in Indianapolis
402 N. Blackford St.
Indianapolis, IN 46202-3274
(317) 274-3642
jarmccar@iupui.edu

Vice Chair 2009
Laurence Hurley, Ph.D.
Keating Bioresearch Building 102
1657 E. Helen St.
University of Arizona
Tucson, AZ 85721
(520) 626-5622
hurley@pharmacy.arizona.edu

Program Chair 2009-2010
Jeff Zablocki, Ph.D.
Gilead Sciences, Inc.
3172 Porter Drive
Palo Alto, CA 94304
(650) 384-8547
jeff.zablocki@cvt.com

Secretary and Public Relations 2008-2010
Patrick M. Woster, Ph.D.
3132 Applebaum Hall
Wayne State University
Detroit, MI 48202
(313) 577-1523
pwoster@wayne.edu

Membership Chair
Yanping Xu, Ph.D.
Lilly Research Laboratories
Lilly Corporate Center DC1910
Indianapolis, IN 46285
(317) 433-1113
xu_yanping@lilly.com

Treasurer 2009-2011
Danny L. Lattin, Ph.D.
4950 Research Park Way
Lawrence, KS 66047
(785) 843-3460
lattind@ku.edu

Academic Councilor 2008-2010
Richard A. Gibbs, Ph.D.
Department of Medicinal Chemistry and Molecular Pharmacology
575 Stadium Mall Drive
Purdue University
West Lafayette, IN 47907-2091
(765) 494-1456
rag@pharmacy.purdue.edu

Academic Councilor 2009-2011
Wendel L. Nelson, Ph.D.
Department of Medicinal Chemistry
College of Pharmacy
University of Washington
Seattle, WA 98195-7610
(206) 543-2209
wlnelson@u.washington.edu

Industrial Councilor 2007-2009
Ravi Nargund, Ph.D.
Merck Research Laboratories
RY 50G-301
P.O. Box 2000
Rahway, NJ 07065
(732) 594-3704
ravi_nargund@merck.com

Industrial Councilor 2009-2011
William Greenlee, Ph.D.
Schering-Plough Research Institute
K15-3
2015 Galloping Hill Road
Kenilworth, NJ 07033,
(908) 740-2220
william.greenlee@spcorp.com

Past Chair 2009
Donald J. Abraham, Ph.D.
Department of Medicinal Chemistry
Virginia Commonwealth University
410 N. 12th Street
Richmond, VA 23298-0581
(804) 828-8183
dabraham@vcu.edu
2. Alternate Councilors and Members-at-Large (Ad Hoc EC Members)

**Academic Alternate Councilor 2008-2010**
Richard A. Glennon, Ph.D.
Department of Medicinal Chemistry
Virginia Commonwealth University
410 N. 12th Street
Richmond, VA 23298-0581
(804) 828-8487
glennon@vcu.edu

**Academic Alternate Councilor 2009-2011**
Thomas E. Prisinzano, Ph.D.
Dept. of Medicinal Chemistry
1251 Wescoe Hall Drive
4070 Malott Hall
Lawrence, Kansas 66045-7582
(785) 864-3267
prisinza@ku.edu

**Industrial Alternate Councilor 2007-2009**
Jasbir Singh, Ph.D.
Vice-President, Medicinal Chemistry
deCODE Chemistry, Inc.
2501 Davey Road
Woodridge, IL 60517
(630) 783-4915
jsingh@decode.com

**Industrial Alternate Councilor 2009-2011**
Peter R. Bernstein, Ph.D.
Department of Chemistry
AstraZeneca Pharmaceuticals
1800 Concord Pike
Wilmington, DE 19803
(302) 886-8966
peter.bernstein@astrazeneca.com

**Member-at-Large (Ad Hoc) 2008-2009**
Andrew Stamford
Schering Plough Research Institute
K15-2545
2015 Galloping Hill Road
Kenilworth NJ, 07033
(908) 740-3481
Andrew.Stamford@spcorp.com

**Member-at-Large (Ad Hoc) 2008-2009**
Yusuf Abul-Hajj
Department of Medicinal Chemistry
308 Harvard St. S.E.
9-151 Weaver-Densford Hall
College of Pharmacy
University of Minnesota
Minneapolis, MN 55455
(612) 624-5987
abulh001@umn.edu

**Editor-in-Chief, Annual Reports in Medicinal Chemistry (2007-2011)**
John E. Macor, Ph.D.
Executive Director, Neuroscience Discovery Chemistry
Bristol-Myers Squibb
5 Research Parkway
Wallingford, CT 06492
(203) 677-7092
john.macor@bms.com

**Foreign Societies Liaison 2009**
Thomas J. Perun, Ph.D.
47731 Old Houston Hwy
Hempstead, TX 77445
tjperun@aol.com
3. Long Range Planning Committee

Laurence Hurley, Ph.D.  
Keating Bioresearch Building 102  
1657 E. Helen St.  
University of Arizona  
Tucson, Arizona 85721  
(520) 626-5622  
thurley@pharmacy.arizona.edu  

Anandan Palani, Ph.D. (2008-2010)  
Schering Plough Research Institute  
205 Galloping Hill Road  
Kenilworth, NJ 07033  
(908) 740-7158  
anandan.palani@spcorp.com  

Michelle L. Lamb, Ph.D. (2008-2010)  
Principal Scientist  
AstraZeneca R&D Boston  
35 Gatehouse Dr.  
Waltham, MA 02451  
(781) 839-4401  
Michelle.Lamb@astrazeneca.com  

Department of Medicinal Chemistry  
University of Minnesota  
308 Harvard St. S.E., 8-101 WDH  
Minneapolis, MN 55454-0353  
(612) 626-6523  
fecik001@umn.edu  

Director, Medicinal Chemistry  
Merck Research Laboratories  
PO Box 2000, RY121E-22  
Rahway, NJ 07065-0900  
(732) 594-7039  
robert_devita@merck.com  

Hsiu-Chung (Ginnie) Yang, Ph.D. (2007-2009)  
Lilly Research Laboratories  
Lilly Corporate Center  
Eli Lilly and Company  
Indianapolis, IN 48285  
(317) 433-2543  
ginnie_yang_hc@yahoo.com  

Dept. of Chemistry and Biochemistry  
Molecular Biology Institute  
5500 Campanile Road, 208 CSL  
San Diego State University  
San Diego, CA 92182-1030  
(619) 993-8609  
mcalpine@chemistry.sdsu.edu  

Tudor I. Oprea (2008-2010)  
Professor, Biochemistry and Molecular Biology  
University of New Mexico School of Medicine  
Albuquerque, New Mexico 87131  
(505) 272-8223  
toprea@salud.unm.edu  

Wyeth Research  
CN 8000  
Princeton, NJ 08510  
(732) 274-4289  
buteraJ@wyeth.com  

Frank Wu, Ph.D. (2008-2010)  
Senior Principal Scientist  
Boehringer- Ingelheim Pharmaceuticals, Inc.  
900 Ridgebury Road/PO Box 368  
Ridgefield, CT 06877  
(203) 791-6317  
frank.wu@boehringer-ingelheim.com  

David G. Hangauer, Ph.D. (2008-2010)  
Associate Professor of Medicinal Chemistry & Chemistry  
Department of Chemistry &  
Senior Vice President for Research &  
Development & Co-Founder  
Kinex Pharmaceuticals, LLC  
359 Natural Sciences Complex  
Box 603000  
University at Buffalo  
The State University of New York  
Buffalo, NY 14260-3000  
(716) 645-6299  
hangauer@buffalo.edu  

Carole A. Bewley, Ph.D. (2009-2011)  
Laboratory of Bioorganic Chemistry, Senior Investigator  
NIDDK, National Institutes of Health  
8 Center Drive, Room 1A-02  
Bethesda, MD 20892-0820  
Phone: 301-594-5187  
caroleb@mail.nih.gov  

Thomas S. Scanlan, Ph.D. (2009-2011)  
Dept of Physiology & Pharmacology  
Oregon Health & Science University  
3181 SW Sam Jackson Park Rd  
Portland, OR 97239  
(503) 494-9292  
scanlant@ohsu.edu
We need your input!

Send your suggestions for symposia for MEDI national meeting scientific programming to any member of the Executive Committee or Long Range Planning Committee. Proposals are reviewed by the Long Range Planning Committee at each national ACS meeting, and symposia are selected one year in advance. The strength of Division programming comes directly through suggestions from individual members.